News
At long last, CoreValve trial gets green light from FDA
“Minneapolis, MN - The long-awaited US trial of the CoreValve transcatheter aortic-valve system is set to begin soon now that the FDA has granted Medtronic an investigational device exemption (IDE) for the pivotal study.”
“The study, which the company expects to begin by the end of the fall, will be conducted at 40 US clinical sites and led by surgeon Dr David Adams (Mount Sinai Medical Center, New York) and interventionalist Dr Jeffrey Popma (Beth Israel Deaconess Medical Center, Boston, MA).”
Page Created: January 08, 2018
Last Updated: January 08, 2018
Share
News & Press
-
Flying cross country amid coronavirus pandemic for heart surgery: One patient’s success story
By Kayla Rivas -
The Mount Sinai Hospital Awarded Highest Quality Rating for Adult Cardiac Valve Surgery
Mount Sinai’s Cardiac Surgeon-in-Chief also receives top rating -
Young Harlem hoopster and activist back in the lineup after life-saving heart surgery
By Molly Crane-Newman and Larry McShane